Clinical Trial Search

Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants

Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001

Primary: Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected…

Primary: 9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder — 13; 24; 158; 129 participants — p=0.0264

Primary: Average Pain Score Over the First 30 Post-operative Minutes Using the CHEOPS Scale — 6.36; 6.57; 6.58 units on a scale

Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for Prediction of Vaginal Delivery Using 2D or 3D Ulrasound — 81; 76; 80; 76 percentage probability — p=<0.01

Primary: Treatment Efficacy Will be Defined as the Number of Patients With Biopsy Proven Acute Rejection at One Year Post-transplant. — 6; 10 participants

Primary: Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score — -0.7; -0.3 units on a scale — p=0.0541

Primary: Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ) — 1912.0; 1783.7; 448.3; 455.3 nanogram per milliliter…

Primary: Progression-Free Survival — 5.9; 6.1 weeks — p=0.1909

Primary: Number of Participants With Adverse Events — 31 participants

Primary: Participants Exhibiting Immune Response — 11 Participants

Primary: Sensitivity of Color Doppler Examination to Detect Major Heart Defects During the Second Trimester of Pregnancy — 39; 9 fetuses

Primary: Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen — 1657.9; 1557.4; 2678.8; 1496.1 mMU/mL — p=<0.001

Primary: Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods — -0.00; -0.11; -0.12 g/dL — p=<0.0001